Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-09T14:12:39.019Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressant and antipsychotic drug prescribing in Lombardy

Published online by Cambridge University Press:  18 May 2011

Mauro Percudani ,
Corrado Barbui ,
Ida Fortino ,
Michele Tansella  and
Lorenzo Petrovich
Mauro Percudani*
Affiliation:
Direzione Generale Sanità, Regione Lombardia, Milano
Corrado Barbui
Affiliation:
Dipartimento di Medicina e Sanità Pubblica, Sezione di Psichiatria e Psicologia Clinica, Università di Verona, Verona
Ida Fortino
Affiliation:
Direzione Generale Sanità, Regione Lombardia, Milano
Michele Tansella
Affiliation:
Dipartimento di Medicina e Sanità Pubblica, Sezione di Psichiatria e Psicologia Clinica, Università di Verona, Verona
Lorenzo Petrovich
Affiliation:
Direzione Generale Sanità, Regione Lombardia, Milano
*
Address for correspondence: Dr. M. Percudani, Direzione Generale Sanità, Regione Lombardia, Unità Organizzativa Programmazione e Sviluppo Piani, Struttura Rete Emergenza Urgenza, Piano Salute Mentale e Piano NPI, Via Pola 9/11, 20122 Milano. Fax: +39-02-6765.3306 E-mail: [email protected]; [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Background – The patterns of antidepressant and antipsychotìc drag prescribing have rarely been studied in large and geographically defined catchment areas. In the present study we examined the prevalence and distribution of antidepressant and antipsychotic prescribing in Lombardy, a northern Italy region of nine million inhabitants. Methods – This study used the Regional Administrative Database of Lombardy. This database includes all prescriptions reimbursed by the National Health System in the population living in this region. All antidepressant and antipsychotic prescriptions dispensed from the 1st January to the 31st December 2001 were extracted and prevalence data calculated by dividing antidepressant and antipsychotic users by the total number of male and female residents in each age group. In addition, from the Regional database of hospital admissions we extracted all patients aged 65 or above with cerebrovascular-related outcomes for the year 2002. The two databases were linked anonymously with the aim of investigating the relationship between exposure to psychotropics and occurrence of cerebrovascular accidents in the elderly. Results – During the study period 404, 238 individuals were dispensed antidepressants, yielding a prevalence of use of 2.85 (95% CI 2.84, 2.87) per 100 males and 5.92 (95% CI 5.90, 5.94) per 100 females. The prevalence of use progressively rose with age in both sexes, with the highest rates in old and very old individuals. The majority of individuals received a pharmacological treatment with selective-serotonin reuptake inhibitors only, slightly more than 12% received a treatment with tricyclic antidepressants. A total of 86, 187 subjects were dispensed antipsychotic agents, yielding a prevalence of use of 0.87 (95% CI 0.86, 0.88) per 100 males and 1.01 (95% CI 1.00, 1.02) per 100 females. The prevalence of use progressively rose with age in both sexes, with the highest rates in old and very old subjects. Concerning the relationship between exposure to second-generation antipsychotics (SGAs) and occurrence of cerebrovascular (CBV) accidents, the analysis showed a significantly increased risk of CBV events in elderly subjects exposed to SGAs in comparison with those exposed to first-generation antipsychotics (FGAs) (3, 31%, 95% CI 2, 95–3, 69 vs. 2, 37%, 95% CI 2, 19–2, 57). Finally the analysis indicated no differences in the proportion of cerebrovascular events in elderly subjects exposed to TCAs and SSRIs. Conclusions – The very high rates of antidepressant and antipsychotic drug prescribing detected in late life suggest the need of characterising these individuals in terms of medical and psychiatric characteristics, needs and quality of life. It also suggests the need for pragmatic clinical trials, carried out in the general practice, with the aim of assessing whether antidepressants are effective in these conditions. The data provide preliminary epidemiological evidence that exposure to SGAs, in comparison with exposure to FGAs, significantly increased the risk of cerebrovascular accidents in the elderly.

Declaration of Interest: none.

Keywords

epidemiologyantidepressantsantipsychoticsprevalencecerebrovascular events
Type
Original Articles
Information
Epidemiology and Psychiatric Sciences , Volume 15 , Issue 1 , March 2006 , pp. 59 - 70
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

BIBLIOGRAFIA

Andretta, M., Font, M., Pinato, S. & Mezzalira, L. (2003). Antidepressivi: confronto tra conoscenza e pratica. XXIV Congresso Nazionale SIFO. Percorsi diagnostico-terapeutici in sanità: obiettivi e responsabilità del farmacista pubblico. Giornale Italiano di Farmacia Clinica 17, 30.Google Scholar
Barbili, C., Broglio, E. & Costa, Laia A. (2003). Cross-sectional database analysis of antidepressant prescribing in Italy. Journal of Clinical Psychopharmacology 23, 31–34.CrossRefGoogle Scholar
Barbui, C., Percudani, M., Fortino, I., Tansella, M. & Petrovich, L. (2005). Past use of selective serotonin reuptake inhibitors and the risk of cerebrovascular events in the elderly. International Clinical Psychopharmacology 20(3), 169–171.Google Scholar
Bland, R.C., Orn, H. & Newman, S.C. (1988). Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatrica Scandinavica, Supplementum 338, 24–32.Google Scholar
Blazer, D.G., Kessler, R.C. & McGonagle, K.A. (1994). The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. American Journal of Psychiatry 151, 979–986.Google Scholar
CERGAS (2005). Rapporto Osservatorio Farmaci (OSFAR), Retrieved November 10, 2005, from http://www.cergas.info/researchID.cfm?id=1041Google Scholar
Clavenna, A., Bonati, M., Rossi, E. & De Rosa, M. (2004). Increase in non evidence based use of antidepressants in children is cause for concern. British Medical Journal 328, 711–712.Google Scholar
Dewa, C.S., Remington, G., Herrmann, N., Fearnley, J. & Goering, P. (2002). How much are atypical antipsychotic agents being used, and do they reach the population who need them? A Canadian experience. Clinical Therapeutics 24, 1466–1476.Google Scholar
Dubini, A., Mannheimer, R. & Pancheri, P. (2001). Depression in the community: results of the first Italian survey. International Clinical Psychopharmacology 16, 49–53.CrossRefGoogle ScholarPubMed
EMEA (2005). EMEA public Statement on the safety of olanzapine. Retrieved November 10, 2005, from http://www.emea.eu.int/pdfs/human/press/pus/085604en.pdfGoogle Scholar
ESEMeD/MHEDEA 2000 Investigators (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica, Supplementum. 420, 21–27.Google Scholar
Hamann, J., Ruppert, A., Auby, P., Pugner, K. & Kissling, W. (2003). Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. International Clinical Psychopharmacology 18, 237–242.CrossRefGoogle Scholar
Hemels, M.E.H., Koren, G. & Einarson, T.R. (2002). Increased use of antidepressants in Canada: 1981–2000. Annals of Pharmacotherapy 36, 1375–1379.CrossRefGoogle ScholarPubMed
Herrmann, N., Mamdani, M. & Lanctot, K.L. (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 161, 1113–1115.CrossRefGoogle ScholarPubMed
Jureidini, J.M., Doecke, C.J. & Mansfield, P.R. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal 328, 879–883.Google Scholar
Kessler, R.C., McGonagle, K.A. & Zhao, S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 51, 8–19.CrossRefGoogle ScholarPubMed
Knottnerus, A. & Dinant, G.J. (1997). Medicine based evidence, a prerequisite for evidence based medicine. British Medical Journal 315, 1109–1110.Google Scholar
Lawrenson, R.A., Tyrer, F. & Newson, R.B. (2000). The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders 59, 149–157.CrossRefGoogle ScholarPubMed
Mann, A.H., Schneider, J. & Mozley, C.G. (2000). Depression and the response of residential homes to physical health needs. International Journal of Geriatric Psychiatry 15, 1105–1112.Google Scholar
McConville, B.J. & Sorter, M.T. (2004). Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. Journal of Clinical Psychiatry 65, Suppl. 6, 20–29.Google ScholarPubMed
Meijer, W.E., Heerdink, E.R., Nolen, W.A., Herings, R.M., Leufkens, H.G. & Egberts, A.C. (2004). Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Archives of Internal Medicine 164, 2367–2370.Google Scholar
Mond, J., Morice, R., Owen, C. & Korten, A. (2003). Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 37, 55–61.Google Scholar
Olfson, M., Shea, S., Feder, A., Fuentes, M., Nomura, Y., Gameroff, M. & Weissman, M.M. (2000). Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Archives of Family Medicine 9, 876–883.Google Scholar
Pariante, C.M. & Tansella, M. (2005). Controversises in antidepressant therapy. Epidemiologia e Psichiatria Sociale 14 (2), 51–54.Google Scholar
Percudani, M., Barbui, C., Fortino, I. & Petrovich, L. (2004a). Antidepressant drug use in Lombardy, Italy: a population based study. Journal of Affective Disorders 83, 169–175.Google Scholar
Percudani, M., Barbui, C., Fortino, I. & Petrovich, L. (2004b). Antipsychotic drug prescribing in the elderly is cause for concern. International Clinical Psychopharmacology 19, 347–350.Google Scholar
Percudani, M., Barbui, C., Fortino, I. & Petrovich, L. (2005a). Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry 38, 128–131.CrossRefGoogle ScholarPubMed
Percudani, M., Barbui, C., Fortino, I. & Petrovich, L. (2005b). Worrying patterns of out-patient psychotropic drug prescribing in children and adolescents. Psychotherapy and Psychosomatic 74, 189–190.Google Scholar
Percudani, M., Barbui, C., Fortino, I. & Petrovich, L. (2005c). Antidepressant drug prescribing among elderly subjects: a population-based study. International Journal of Geriatric Psychiatry 20, 113–118.CrossRefGoogle ScholarPubMed
Percudani, M., Barbui, C., Fortino, I., Tansella, M. & Petrovich, L. (in press). Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical PsychopharmacologyGoogle Scholar
Pietram, C., Barbui, C., Poggio, L. & Tognoni, G. (2001). Antidepressant drug prescribing in Italy, 2000: analysis of a general practice database. European Journal of Clinical Pharmacology 57, 605–609.Google Scholar
Rosholm, J.U., Andersen, M. & Gram, L.F. (2001). Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. European Journal of Clinical Pharmacology 56, 923–929.Google Scholar
Rothbard, A.B., Kuno, E. & Foley, K. (2003). Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29, 531–540.Google Scholar
Santamaria, B., Perez, M., Montero, D., Madurga, M. & de Abajo, F.J. (2002). Use of antipsychotic agents in Spain through 1985–2000. European Psychiatry 17, 471–476.Google Scholar
Scillia, C.V., Maione, M.R., Piro, B., Ferraiolo, R., Talarico, A., De Stefano, G., Sacco, F., Servadei, F., Garaffo, C., Di Lorenzo, R. & De Marco, G. (2003). Studio retrospettivo multicentrico sul?utilizzo degli antipsicotici classici verso quelli atipici in quattro AA.SS.LL. della Calabria. XXIV Congresso Nazionale SIFO. Percorsi diagnostico-terapeutici in sanità: obiettivi e responsabilità del farmacista pubblico. Giornale Italiano di Farmacia Clinica 17, 30–31.Google Scholar
Smith, D. A. & Beier, M.T. (2004). Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypothesis for an underlying mechanism. Journal of the American Medical Association 5, 129–132.Google Scholar
Whittington, C.J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A. & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 1341–1345.Google Scholar
Zimmerman, M., Mattia, J.I. & Posternack, M.A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry 159, 469–473.CrossRefGoogle ScholarPubMed